Abstract
Classical Hodgkin Lymphoma (cHL) is a B cell-derived lymphoid malignancy, affecting 2.5–3/100,000 people per year. To date, in patients diagnosed with advanced cHL no reliable tool is able to—a priori—distinguish the subset of patients at high risk for relapse or refractory disease. Clinical risk indices for cHL, such as the International Prognostic Score (IPS), have not been successfully applied as a treatment decision tool in advanced stage cHL [1]. In this study we show, that a previously published gene expression-based predictor in advanced stage cHL patients treated with ABVD [2] does not prove prognostic in 401 BEACOPP-treated advanced stage cHL patients. Using transcriptome profiling, we identified however that three individual genes, PDGFRA, TNFRSF8 (encoding CD30) and CCL17 (encoding TARC), were significantly associated with progression-free survival (PFS) after multiple test correction in the BEACOPP-treated cohort, highlighting the potential of a modified gene expression profiling approach for pre-treatment risk assessment.
Highlights
6 Statistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany study we show, that a previously published gene expression-based predictor in advanced stage Classical Hodgkin Lymphoma (cHL) patients treated with ABVD [2] does not prove prognostic in 401 BEACOPP-treated advanced stage cHL patients
We identified that three individual genes, plateletderived growth factor receptor A (PDGFRA), TNFRSF8 and CCL17, were significantly associated with progression-free survival (PFS) after multiple test correction in the BEACOPP-treated cohort, highlighting the potential of a modified gene expression profiling approach for pre-treatment risk assessment
We observed that the International Prognostic Score (IPS) was both significantly prognostic for overall survival (OS) and PFS in BEACOPP-treated patients (Table 1D, p = 0.0036 and p = 0.0027, respectively)
Summary
6 Statistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany study we show, that a previously published gene expression-based predictor in advanced stage cHL patients treated with ABVD [2] does not prove prognostic in 401 BEACOPP-treated advanced stage cHL patients. The adjusted gene predictor produced scores that correlated strongly with the original scores in the previously published Vancouver data set of both the training and the validation cohort
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
